NEW YORK, Dec. 12, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Ligand Pharmaceuticals Inc. (“Ligand”) (NASDAQ:LGND) between November 9, 2015 and November 14, 2016. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Southern District of California. To get more information go to:
http://www.zlk.com/pslra/ligand-pharmaceuticals
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that during the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Ligand overstated the value of certain Deferred Tax Assets by approximately $27.5 million; (2) Ligand’s outstanding convertible senior unsecured notes due 2019 should have been classified as short-term debt rather than long-term debt as of December 31, 2015; (3) Ligand did not maintain effective controls over the accuracy and presentation of the accounting for income taxes related to complex transactions; (4) in turn, Ligand lacked effective internal control over financial reporting; and (5) as a result, Defendants’ statements about Ligand’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in Ligand you have until January 17, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
OpenAI Explores Massive Funding Round at $750 Billion Valuation
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 



